DSGN
Design Therapeutics Inc
12.00$
-3.6%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -3.4% | -3.7% | -3.3% | -3.0% | -3.6% | -5.8% | -6.1% | -5.0% | +6.8% | +1.9% | -6.6% | |
| – | -3.4% | -3.8% | -3.3% | -2.9% | -3.6% | -5.8% | -5.9% | -4.9% | +7.1% | +1.5% | -6.6% | |
| – | -24.1% | +38.7% | +55.5% | -33.6% | -25.6% | -39.4% | +44.2% | -23.4% | +11.7% | -24.2% | +1.1% | |
| – | -3.1% | -3.9% | -3.6% | -2.7% | -3.4% | -6.4% | -5.8% | -4.8% | +6.7% | +1.4% | -6.9% | |
| – | +18.5% | +17.0% | -16.6% | -15.7% | +7.1% | +11.2% | -4.1% | +2.4% | +21.4% | +8.7% | -2.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -19.8% | -22.8% | -9.7% | +10.0% | +8.9% | -4.4% | +3.1% | +22.3% | +13.7% | -9.6% | +7.1% | |
| – | -22.3% | -26.3% | -9.9% | +16.2% | +13.9% | -2.7% | +6.2% | +27.7% | +16.8% | -21.9% | +10.3% | |
| – | +2.7% | +2.8% | +2.9% | +2.8% | +2.8% | +2.6% | +2.8% | +2.6% | +2.8% | -39.8% | – | |
| – | -12.1% | -29.3% | -5.5% | +13.3% | +48.7% | +45.5% | -68.1% | +88.8% | +20.9% | -1.6% | +38.0% | |
| – | -2.6% | -2.9% | -3.1% | -3.4% | -4.1% | -5.9% | -6.5% | -6.3% | +6.4% | +2.6% | -7.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.3% | +0.6% | +0.1% | +0.1% | +0.1% | +0.1% | +0.2% | +0.2% | +0.7% | +7.2% | +1.7% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.